An Open-Label, Single-dose, Randomized, Crossover Study to Determine the Bioavailability of Alogliptin 12.5 mg and Metformin 1000 mg When Administered as Individual Tablets and as a Fixed-Dose Combination Tablet (Alogliptin FDC With Metformin) in Russian Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 07 Oct 2016
At a glance
- Drugs Alogliptin (Primary) ; Alogliptin/metformin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Takeda
- 01 Jun 2016 Status changed from not yet recruiting to completed.
- 10 Feb 2016 Planned End Date changed from 1 Feb 2016 to 1 May 2016 as reported by ClinicalTrials.gov.
- 10 Feb 2016 Planned primary completion date changed from 1 Feb 2016 to 1 May 2016 as reported by ClinicalTrials.gov.